SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Sérgio Barra, Simon Fynn, Untreated atrial fibrillation in the United Kingdom: Understanding the barriers and treatment options, Journal of the Saudi Heart Association, 2015, 27, 1, 31

    CrossRef

  2. 2
    Ying Zheng, Sonja V. Sorensen, Ann-Katrin Gonschior, Herbert Noack, Jutta Heinrich-Nols, Tom Sunderland, Anuraag R. Kansal, Comparison of the Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation in a UK Setting, Clinical Therapeutics, 2014, 36, 12, 2015

    CrossRef

  3. 3
    Talitha I. Verhoef, William K. Redekop, Fazila Hasrat, Anthonius de Boer, Anke Hilse Maitland-van der Zee, Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings, American Journal of Cardiovascular Drugs, 2014, 14, 6, 451

    CrossRef

  4. 4
    Andreas Clemens, Siyang Peng, Sarah Brand, Martina Brueckmann, Anuraag Kansal, Jonathan Lim, Herbert Noack, Stephen Sander, Sonja Sorensen, Efficacy and Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin in Atrial Fibrillation in Different Age Subgroups, The American Journal of Cardiology, 2014, 114, 6, 849

    CrossRef

  5. 5
    Sonja V. Sorensen, Siyang Peng, Brigitta U. Monz, Carole Bradley-Kennedy, Anuraag R. Kansal, A Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial Fibrillation, PharmacoEconomics, 2013, 31, 7, 589

    CrossRef